CA
RXST icon

Clearstead Advisors’s RxSight RXST Stock Holding History

Clearstead Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$9 – 3174
2025
Q3 		$9 Buy
+1
New +$9 ﹤0.01% 3049

Other funds holding RXST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Clearstead Advisors's RXST Position: Q4 2025 in Review

Clearstead Advisors sold out of RxSight (RXST) in Q4 2025, closing a stake of 1 share — an estimated $9 sold.

Clearstead Advisors first reported a position in RXST in Q3 2025 and held it in 1 quarter. The position peaked at $9 in Q3 2025. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

  • Clearstead Advisors reported no remaining RxSight position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 1 RxSight share in Q4 2025, an estimated $9.
  • Clearstead Advisors first reported a position in RxSight in Q3 2025 and held it in 1 quarter.
  • Clearstead Advisors's RxSight position peaked at $9 in Q3 2025.
  • 163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.